Effect of fenofibrate combined with insulin in the treatment of type 2 diabetes mellitus complicated with nonalcoholic fatty liver disease

Abstract

Abstract: Objective To compare the effect of fenofibrate combined with insulin in the treatment of type 2 diabetes mellitus (T2DM) complicated with nonalcoholic fatty liver disease and its influence on liver function, blood glucose content and vascular endothelial function.Methods The clinical data and follow-up data of 150 patients with type 2 complicated with nonalcoholic fatty liver disease were analyzed retrospectively, they were divided into control group (n=70) and observation group (n=80) according to the random number method. The patients in the control group received the guidance of healthy diet and reasonable exercise, and received insulin treatment. The observation group was treated with fenofibrate on the basis of the control group, and both groups were treated for 3 months. The clinical efficacy, liver function, blood glucose content and vascular endothelial function before and after treatment were compared between the two groups.Results The clinical effective rates of the observation group and the control group were 92.50% and 75.71% (P<0.05); compared with those before treatment, ALT, AST, FPG, 2hPG, HbA1c in the two groups were decreased after treatment (P<0.05), and the decline in the observation group was greater than that in the control group (P<0.05). After treatment, ET and TXB2 in the two groups were decreased (P<0.05), and PGF1 and NO were significantly increased (P<0.05) in the observation group. The improvement degree was significantly greater than that in the control group (P<0.05).Conclusion Fenofibrate combined with insulin in the treatment of T2DM patients with nonalcoholic fatty liver disease has significant clinical curative effect, which can improve renal function, reduce blood glucose level and improve vascular endothelial function, which is worthy of further clinical promotion.

Key words: Fenofibrate, Insulin, Type 2 diabetes mellitus

LI Zhen-zhen, BAI Yang, HUANG Ting. Effect of fenofibrate combined with insulin in the treatment of type 2 diabetes mellitus complicated with nonalcoholic fatty liver disease[J]. Chinese Hepatolgy, 2022, 27(1): 103-105.

References

[1] 邢宇锋,翟芬芬,韩志毅,等.疏肝消脂方防治高脂饮食诱导的非酒精性脂肪性肝炎大鼠的实验研究.中西医结合肝病杂志2018,28:166-168.
[2] Shao H, Wu R, Cao L,et al. Trelagliptin stimulates osteoblastic differentiation by increasing runt-related transcription factor 2 (RUNX2): atherapeutic implication in osteoporosis. Bioengineered,2021,12:960-968.
[3] 刘烨,朱亦堃,刘炯.基础-餐时胰岛素强化联合西格列汀治疗新诊断2型糖尿病伴非酒精性脂肪肝的疗效及其对血管内皮功能的影响.中西医结合心脑血管病杂志,2020,018:1137-1141.
[4] Ren H, Zhao L, Zou Y, et al. Association between atherosclerotic cardiovascular diseases risk and renal outcome in patients with type 2 diabetes mellitus. Ren Fail, 2021, 43:477-487.
[5] 毛重山,殷辉,肖二辉,等.非诺贝特对非酒精性脂肪性肝病合并2型糖尿病患者血脂、血管内皮功能和肝纤维化指标的影响.实用肝脏病杂志,2020.14:98-101.
[6] Cheng L, Wang J, Dai H, et al. Brown and beige adipose tissue: a novel therapeutic strategy for obesity and type 2 diabetes mellitus. Adipocyte,2021,10:48-65.
[7] 毛重山,殷辉,肖二辉,等.非诺贝特对非酒精性脂肪性肝病合并2型糖尿病患者血脂,血管内皮功能和肝纤维化指标的影响.实用肝脏病杂志,2020,23:50-53.
[8] 刘素青.利拉鲁肽对2型糖尿病合并非酒精性脂肪性肝病患者血糖,血脂水平的影响.河南医学研究,2020,29:1138-1140.
[9] Kazi M, Alqahtani A, Ahmad A, et al. Development and optimization of sitagliptin and dapagliflozin loaded oral self-nanoemulsifying formulation against type 2 diabetes mellitus. Drug Deliv,2021,28:100-114.
[10] 张丹,文代艳,施春晶,等.非诺贝特对非酒精性脂肪性肝病小鼠模型肠道菌群多样性的影响.临床肝胆病杂志,2020,36:829-834.
[11] 王艳妮,李转霞.二甲双胍联合利拉鲁肽对2型糖尿病合并非酒精性脂肪肝患者胰岛β细胞功能、肝功能及外周血Treg细胞的影响.医学临床研究,2018,34:11-14.
[12] Zabidi NA, Ishak NA, Hamid M, et al. Inhibitory evaluation of Curculigo latifolia on α-glucosidase, DPP (IV) and in vitro studies in antidiabetic with molecular docking relevance to type 2 diabetes mellitus. J Enzyme Inhib Med Chem,2021,36:109-121.
[13] 姜峥嵘,陈静.利拉鲁肽治疗2型糖尿病合并非酒精性脂肪性肝病的临床研究.中国临床药理学杂志,2020,34:234-236.
[14] 褚韦韦,官莉莉,黄迪华,等.糖调节异常合并非酒精性脂肪性肝病患者血内皮素-1与胰岛素抵抗的相关性研究.浙江医学,2018,40:56-58.
[15] 常薪霞,张林杉,夏明锋.2型糖尿病伴非酒精性脂肪性肝病患者血常规指标与肝脏脂肪含量的相关性.中国临床医学2019,25:692-696.
[16] Guzauskas GF, Rind DM, Fazioli K, et al. Cost-effectiveness of oral semaglutide added to current antihyperglycemic treatment for type 2 diabetes. J Manag Care Spec Pharm,2021,27:455-468.
[17] Bhandari M, Kosta S, Khurana M, et al. Emerging Procedures in Bariatric Metabolic Surgery. Surg Clin North Am,2021,101:335-353.
[18] 黄海涛,叶攀,谈发明,等.非诺贝特联合依折麦布治疗2型糖尿病合并高脂血症对代谢指标及血管内皮功能的影响.徐州医科大学学报,2019,24:32-36.
[19] Albaugh VL, Kindel TL, Nissen SE, et al. Cardiovascular Risk Reduction Following Metabolic and Bariatric Surgery. Surg Clin North Am,2021,101:269-294.
[20] Ismail M, Nagaraj D, Rajagopal M, et al. Is weight regaining significant post laparoscopic Roux-en-Y gastricbypass surgery-A 5-year follow-up study on Indian patients. J Minim Access Surg, 2021,17:159-164.